Zuclopenthixol dihydrochloride for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 11, 2017, Pages

  Bryan, Edward J ^a   Purcell, Marie Ann ^b   Kumar, Ajit ^c  

^a SHEFFIELD HEALTH AND SOCIAL CARE NHS FOUNDATION TRUST   (United Kingdom)

^b General Practitioner   (United Kingdom)

^c LEEDS COMMUNITY HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; HALOPERIDOL; PERPHENAZINE; PLACEBO; RISPERIDONE; SULPIRIDE; TIOTIXENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL; CLOPENTHIXOL; NEUROLEPTIC AGENT;

COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; INTENTION TO TREAT ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; META ANALYSIS; MOTOR DYSFUNCTION;

ANTIPSYCHOTIC AGENTS; CLOPENTHIXOL; HUMANS; MOVEMENT DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 85034097231     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005474.pub2     Document Type: Review

References (157)

1. Aaes-Jorgensen T, Gravem A, Jorgensen A. Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)-trans(E)-clopenthixol. Acta Psychiatrica Scandinavica Supplementum 1981;294:70-7. [MEDLINE: 82178887; PMID 6951396]6946944
2. Arango C, Bombin I, Gonzalez-Salvador T, Garcia-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry 2006;21(1):34-40. [MEDLINE: 16360311]6946946
3. Bombin I, Arango C. Antipsychotic treatment adherence and violence in schizophrenia outpatients: a randomized prospective trial. European Neuropsychopharmacology 2004;14(Suppl 3):S289. 6946947
4. Balasubramanian K, Baloch N, Briscoe MH, Chattree S, Cooper CJ, Durani SK, et al. A double blind multicentre comparison of oral zuclopenthixol and oral chlorpromazine in the treatment of acute psychosis. British Journal of Clinical Research 1991;n/a:149-56. [MEDLINE: 69006168; PMID 5600894]6946949
5. Ban TA, Lehmann HE, Sterlin C, Climan M. Comprehensive clinical studies with thiothixene. Diseases of the Nervous System 1975;36(9):473-7. [MEDLINE: 76021805; PMID 240651]6946951
6. Lehmann HE, Ban TA. Thiothixene versus chlorprothixene versus clopenthixol. Psychopharmacology Bulletin 1970;6(4):118-20. [13027]6946952
7. Sterlin C, Ban TA, Jarrold L. The place of thiothixene among the thioxanthenes. Current Therapeutic Research Clinical and Experimental 1972;14(4):205-14. [MEDLINE: 72182264; PMID 4623599]6946953
8. [Title only available in Chinese characters]. Shandong Archives of Psychiatry 2005;18(3):175-6. 6946955
9. Dehnel LL, Vestre ND, Schiele BC. A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Current Therapeutic Research Clinical and Experimental 1968;10:169-76. [MEDLINE: 68242121; PMID 4967871]6946957
10. Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthoj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in fisrt-episode drug-naive schizophrenic patients. CNS Spectrums. United States of America, 2004; Vol. 9, issue 5:364-74. [MEDLINE: 15115949]3033628
11. Fischer-Cornelssen KA, Ferner UJ. An example of European multicentre trials: multispectral analysis of clozapine. Psychopharmacology Bulletin 1976;12:34-9. 3033630
12. Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research 2007;154(3):199-208. [MEDLINE: 17360162]6946959
13. Glenthoj B, Fagerlund B, Rasmussen H, Pinborg L, Svarer C, Friberg L, et al. Extrastriatal dopamine D2/D3-receptors in drug-naïve first-episode schizophrenic patients: relation to psychopathology, cognition and treatment outcome. International Journal of Neuropsychopharmacology 2008;11(Suppl 1):6-7. 6946960
14. Glenthoj B, Glenthoj A, Jagersma E, Pagsberg AK, Hemmingsen RP, Svarer C, et al. Effects of typical and atypical antipsychotic medication on caudate nucleus volume in first-episode schizophrenic patients: relation to dopamine d2/3 receptor occupancy psychopathology and extrapyramidal side-effects. Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt. 2005. 6946961
15. Gravem A, Engstrand E, Guleng RJ. Cis(Z)-clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. A double-blind clinical investigation. Acta Psychiatrica Scandinavica 1978;58(5):384-8. [MEDLINE: 79058923; PMID 362830]3033636
16. Gravem A, Bugge A. Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. A double-blind clinical investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:13-24. [MEDLINE: 82178878; PMID 7041515]3033638
17. Heikkila L, Karsten D, Valli K. A double-blind clinical investigation of cis(Z)-clopenthixol and clopenthixol in chronic schizophrenic patients. Acta Psychiatrica Scandinavica Supplementum 1981;294:25-9. [MEDLINE: 82178880; PMID 7041516]3033640
18. Heikkila L, Eliander H, Vartiainen H, Turunen M, Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multicentre study. Current Medical Research and Opinion 1992;12(9):594-603. [EMBASE 1992128093]6946963
19. Heikkila L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. Acta Psychiatrica Scandinavica Supplementum 1981;294:30-8. [MEDLINE: 82178881; PMID 7041517]6946964
20. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatrica Scandinavica 1995;91(4):271-7. 6946966
21. Huttunen MO, Piepponen T. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes. European Psychiatry 1994;9(Suppl 1):85. 6946967
22. Moller HJ, Huttunen MO. The prevalence of extrapyramidal symptoms during short and long term treatment with risperidone. 7th Biennial European Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland 1994;11(2):106. [MEDLINE: 94001724; PMID 8104468]6946968
23. Kingstone E, Kolivakis T, Kossatz I. Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics. Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie 1970;3(1):41-5. [MEDLINE: 70164847; PMID 4909377]3033649
24. Kordas SK, Kazamias NG, Georgas JG, Papadokostakis JG. Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients. British Journal of Psychiatry 1968;114(512):833-6. [MEDLINE: 68329665; PMID 4874163]3033651
25. Mahadevan K, Gadhvi HM, Suri AK, Hussain MF, Sharma VK, Sharma SK, et al. A multicentre comparison of oral zuclopenthixol dihydrochloride and oral sulpiride in the treatment of acute schizophrenia. British Journal of Clinical Research 1991;2:13-20. [Cochrane Library CN-00282616]3033653
26. Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Stromgren LS. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study. Pharmacopsychiatry 1987;20(4):147-54. [MEDLINE: 87290070; PMID 3615572]3033655
27. Serafetinides EA. Consistency and similarity of drug EEG responses in chronic schizophrenic patients. International Pharmacopsychiatry 1973;8(4):214-6. [MEDLINE: 74083340; PsycINFO 52-05954; PMID 4589640]6946974
28. Serafetinides EA. Voltage laterality in the EEG of psychiatric patients. Diseases of the Nervous System 1973;34(3):190-1. [MEDLINE: 73210072; PsycINFO 1973-29665-001; PMID 4715636]6946975
29. Serafetinides EA, Clark ML. Psychological effects of single dose antipsychotic medication. Biological Psychiatry 1973;7(3):263-7. [MEDLINE: 74051947; PsycINFO 52-03694; PMID 4586833]6946970
30. Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. Journal of Nervous and Mental Disease 1972;154(1):31-42. [MEDLINE: 72081124; PMID 4550211]6946971
31. Serafetinides EA, Willis D. A method of quantifying EEG for psychopharmacological research. International Pharmacopsychiatry 1973;8(4):245-7. 6946973
32. Serafetinides EA, Willis D, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Journal of Nervous and Mental Disease 1972;155(5):366-9. [MEDLINE: 73029970; PMID 4563078]6946972
33. Wang R. Double blind study of clopenthixsol treating schizophrenia. Medical Journal of Chinese Civil Administration 1995; Vol. 7, issue 1:4-5, 7. 3033664
34. Aaes-Jorgensen T. Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta Psychiatrica Scandinavica Supplementum 1981;294:64-9. [MEDLINE: 82178886; PMID 6951395]3033666
35. Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatrica Scandinavica Supplementum 1980;279:77-91. [MEDLINE: 80262296; PMID 6996426]3033668
36. Al Haddad MK, Kamel C, Mawgood MA, Sequeria RP. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. Arab Journal of Psychiatry 1996;7(1):44-54. [PsycINFO 2001-16512-004]3033670
37. Arango C, Bombýn I, BobeśJ, Gonzalez-, Cabeza Garcýa-, Salvador MT. Prediction and prevention of violence in schizophrenia outpatients: preliminary report. Schizophrenia Research 2002;53(3 Suppl.1):233. [MEDLINE: 2003183416]3033672
38. Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ, Fensbo C, Gravem A, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica 1993;37(1):48-58. [MEDLINE: 93142586; PMID 8093824]3033674
39. Bereen FJ, Harte FB, Maguire J, Singh AN. The use of oral zuclopenthixol in the treatment of functional psychotic illness. Pharmatherapeutica 1987;5(1):61-8. 3033676
40. Bhattacharya SN, Ghoshal J, Sharma SK, Halstead N, John B, Launer MA, et al. Acute functional psychoses:treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets. Pharmatherapeutica 1987;5(1):1-8. 3033678
41. Bobon D, de Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study. 2nd Congress of the European College of Neuropsychopharmacology; 1989 May 24-26; Gothenburg, Germany. 1989. [MEDLINE: 76021805; PMID 240651]3033680
42. Bobon D, de Bleeker E. Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study. New Strategies in the Treatment of Aggressive, Acutely Psychotic Patients. Proceedings of the 8th World Congress of Psychiatry; 1989 October 13-19, Athens, Greece. Excerpta Medica, 1989:47-59. [MEDLINE: 76021805; PMID 240651]3033681
43. Bourdouxhe S, Mirel J, Denys W, Bobon D. Zuclopenthixol acetate and haloperidol in acute psychoses - results of the AMDP subgroup of a Belgian multicenter study [L'acetate de zuclopenthixol et l'haloperidol dans la psychose aigue - Resultats du sous groupe AMDP d'une etude multicentrique belge]. Acta Psychiatrica Belgica 1987;87(2):236-44. [MEDLINE: 87295330; PsycINFO 26-73137; PMID 3618274]3033683
44. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [MEDLINE: 95351128; PMID 7542829]6946977
45. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Unpublished Report submitted to Human Psychopharmacology Clinical and Experimental 1996. [MEDLINE: 95351128; PMID 7542829]6946978
46. Brook S, Berk M, Selemani S, Kolloori J, Nzo I. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Human Psychopharmacology 1998;13(1):17-20. [EMBASE 1998035700]6946979
47. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72:449-54. 3033689
48. Chin CN, Hamid AR, Philip G, Ramlee T, Mahmud M, Zulkifli G, et al. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Medical Journal of Malaysia 1998;53(4):365-71. [MEDLINE: 74083340; PsycINFO 52-05954; PMID 4589640]3033691
49. Chouinard G, Safadi G, Beauclair L. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Journal of Clinical Psychopharmacology 1994;14(6):377-84. [MEDLINE: 95190073; PMID 7884017]3033693
50. Chouinard G, Safadi G, Beauclair L. The management of acutely schizophrenic patients newly admitted from the emergency room: a double-blind clinical trial comparing zuclopenthixol acetate and liquid haloperidol. Modern Trends in the Treatment of Chronic Schizophrenia. Proceedings of a Symposium; 1991 June 10, Florence, Italy. Excerpta Medica, 1991:35-43. [MEDLINE: 95190073; PMID 7884017]3033694
51. Clark. Sordinol versus chlorpromazine versus placebo. Psychopharmacology Bulletin 1969;3:54-6. [01003]3033696
52. CTRI-2014-07-004712. Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine. Http://apps.who.int/trialsearch/Trial.aspx?TrialID=CTRI/2014/07/004712 2014. 3033698
53. Mythri SV, Tharyan P, Sunder S, Kattula D, Kirubakaran R, Adams CE. Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine [A comparative study of the effects of an intramuscular injection of zuclopenthixol acetate versus an intramuscular injection of a combination of haloperidol plus promethazine in people with violence or agitation presenting to a psychiatric hospital as an emergency]. Study Protocol 2013. 3033699
54. Den Boer JA, Vahlne JO, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15(3):179-89. [EMBASE 2000170004]3033701
55. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatrica Scandinavica Supplementum 1980;279:10-28. [MEDLINE: 80262290; PMID 6931470]3033703
56. Dencker SJ, Malm U, Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta Psychiatrica Scandinavica Supplementum 1980;279:55-63. [MEDLINE: 80262294; PMID 6931473]3033704
57. Dom R, De Mesmaecker L, van den Broucke M, van Hest T, Baro F. Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot. Acta Psychiatrica Scandinavica 1978;57(4):299-304. [MEDLINE: 78207721; PMID 352094]3033706
58. Fagerlund B, Mackeprang T, Gade A, Glenthoj BY. Effects of risperidone and zuclopenthixol on cognitive deficits in drug-naive first episode schizophrenic patients. Schizophrenia Research 2003;60:133-4. [CN-00394142]3033708
59. Fan S, Sun ZG, Li J. The comparison of effects of clopenthixal and clozapine in the treatment of schizophrenia. Acta Acadimae Medicinae Qingdao 1999; Vol. 35, issue 2:125-7. 3033710
60. Fensbo C. Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients - A controlled multicenter study. Meeting of the Scandinavian Society for Psychopharmacology (1989, Copenhagen, Denmark) [Zuclopenthixol acetat, haloperidol og zuclopenthixol i behandling af akut psykotiske patienter. En kontrolleret multicenterundersogelse]. Nordisk Psykiatrisk Tidsskrift 1990;44(3):295-7. [PsycINFO 28-73892]3033712
61. Fricchione Parise V, Balletta G, Manna G. Risperidone depot versus zuclopenthixol depot for schizophrenia and schizophrenialike psychoses: Real world outcomes. European Neuropsychopharmacology 2010; Vol. 1:472-3. 3033714
62. Galderisi S, Maj M, Mucci A, Bucci P, Kemali D. QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry 1994;35(6):367-74. [MEDLINE: 94289546; EMBASE 1994114037; PMID 8018782]3033716
63. Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen R. Effects of antipsychotics on information-processing and extrastriatal dopamine d2/d3 receptors in first-episode drug-naive schizophrenic patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico. 2000:191. [MEDLINE: 95275743; PMID 7756183]3033719
64. Glenthj BY, Mackeprang T, Fagerlund B, Hemmingsen RP. Effects of antipsychotic treatment on prepulse inhibition of the startle response (ppi) and cognition in first episode drug-naive schizophrenic patients. Schizophrenia Research 2001;49(1, 2):133. [PsycINFO 2001-16512-004]3033718
65. Gravem A, Elgen K. Cis(Z) clopenthixol. The neuroleptically active isomer of clopenthixol. A presentation of five double blind clinical investigations and other studies with cis(Z) clopenthixol (Cisordinol(R), Clopixol(R)). Acta Psychiatrica Scandinavica, Supplementum 1981;64(294):5-12. [MEDLINE: 82178884; PMID 6122337]3033721
66. Gravem Arne, Tove AJ. Co-injection of zuclopenthixol acetate and zuclopenthixol decanoate. Nordisk Psykiatrisk Tidsskrift 1990;44(4):403-5. [PsycINFO 78-07960]3033722
67. Hicklin A, Angst J. Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses [Retrospektive und prospektive Studie uber die klinische Wirkung von Clopenthixol (Sordinol) bei endogenen Psychosen]. Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine 1967;97(19):615-21. [MEDLINE: 69006168; PMID 5600894]3033724
68. Hovens JEJM, Beijeman S, Tollenar J, Dries PJT, Loonen AJM. Risperidone versus zuclopenthixol in acute psychosis in emergency psychiatry: a prospective naturalistic study. Journal of the European College of Neuropsychopharmacology 2003;13(4):S293. 3033726
69. Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. Journal of Psychopharmacology 2005; Vol. 19, issue 1:51-7. [MEDLINE: 15671129]3033728
70. Huang SH, Pan YH, Wu FY, Qiu YP. Comparison of clopenthixol decanoate to chlorpromazine in the treatment of schizophrenia. Chinese General Practice 2001;4(10):775-6. [CN-00393723]3033730
71. Karsten D, Kivimaki T, Linna SL, Pollari L, Turunen S. Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(Z)-clopenthixol and haloperidol. Acta Psychiatrica Scandinavica Supplementum 1981;294(64):39-45. [MEDLINE: 82178882; PMID 7041518]3033732
72. Knegtering H, Castelein S, Van Der Linde J, Bous J. Sexual dysfunctions and serum prolactin levels in patients using risperidone or quetiapine: a randomised trial. Schizophrenia Research 2002;53(3 Suppl 1):163. 3033734
73. Koskinen T, Wistedt B, Thelander S. Zuclopenthixol decanoate vs haloperidol decanoate: a double-blind comparative trial. 5th World Congress of Biological Psychiatry; 1991 Jun 9-14; Florence, Italy. 1991:563-5. [MEDLINE: 95275743; PMID 7756183]3033736
74. Kristiansen KT, Mackeprang T, Fink-Jensen A, Hemmingsen RP, Glenthj BY. Effects of antipsychotics and other agents on prepulse inhibition of the starlte response(ppi). Schizophrenia Research 2001;49(1, 2):216. [PsycINFO 2001-16512-004]3033738
75. Kristiansen KT, Mackeprang T, Glenthoj BY. Acute effects of antipsychotics and diazepam on prepulse inhibition of the startle response. Schizophrenia Research 2003; Vol. 60, issue 1 Suppl 1:100. 3033740
76. Lamure M, Toumi M, Chabannes J-P, Dansette G-Y, Benyaya J, Hansen K. Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis. International Journal of Psychiatry in Clinical Practice 2003;7(3):177-85. 3033742
77. Lemmens P, De Smedt G, Gheuens J, Tritsmans L. Efficacy of risperidone in the treatment of schizophrenia. Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland 1994; Vol. 11, issue 2:106. 3033744
78. Liu P, Bian H, Chen H. Observation of clinical effect of clopixol-acuphase injection for acute psychosis. Chinese Journal of Pharmaco Epidemiology. 1997; Vol. 6, issue 4:202-4. 3033746
79. Liu S. A follow-up of effects of sustain treatment of clopixol and cpz in schizophrenic patients. Sichuan Mental Health. 1998; Vol. 11, issue 3:162-3. 3033748
80. Loza B, Kucharska-Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores. European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey) 2001;11(3):285. [14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2103#]3033750
81. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. European Neuropsychopharmacology 1991;1(4):541-8. [EMBASE 1998035700]3033752
82. Mackeprang T, Fagerlund B, Videbaek C, Hemmingsen RP, Glenthoj BY. Extrastriatal dopamine(d2/d3)-receptor occupancy and cognition in first episode schizophrenic patients. Schizophrenia Research 2001;49(Suppl.1, 2):194. [LMD163341]3033754
83. Malt UF, Nystad R, Bache T, Noren O, Sjaastad M, Solberg KO, et al. Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. British Journal of Psychiatry 1995;166(3):374-7. [MEDLINE: 95307869; PMID 7788130]3033756
84. Mann BS, Moslehuddin KS, Owen RT, Clayton AR, Rohatgi KK, Sud P, et al. A clinical assessment of zuclopenthixol dihydrochloride ('Clopixol Tablets') in the treatment of psychotic illness. Pharmatherapeutica 1985;4(6):386392. 3033758
85. Martyns Yellowe IS. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry. West African Journal of Medicine 1993;12(2):110-3. [MEDLINE: 94001724; PMID 8104468]3033760
86. Martyns-Yellowe IS. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West African Journal of Medicine 1994;13(4):200-3. [MEDLINE: 95275743; PMID 7756183]3033761
87. Mazurek I, Loza B, Lecyk A. Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. Journal of the European College of Neuropsychopharmacology 2003;13(4):S347. [P.2.156]3033763
88. Meyers C, Lhoas JP, Huvelle R. Rediscovery of a neuroleptic drug in a new form: clopenthixol [Redecouverte d'un neuroleptique sous une autre presentation: le clopenthixol]. Schweizerische Rundschau fur Medizin Praxis 1972;61(26):869-71. [Cochrane Library CN-00282616]3033765
89. Mosolov SN, Molodetskikh AV, Eryomin AV, Graikov GM, Nourislamov SV. Effect and tolerability of Clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomized investigation. Sotsial'Naia I KlinIcheskaia Psikhiatria 2000;10(2):47-52. [MEDLINE: 68242121; PMID 4967871]3033767
90. NCT00206960. Effects of classical and atypical antipsychotics on dopamine receptor binding of 123i-epidepride, cognition, startle response and extrapyramidal side-effects in drug-naive first-episode schizophrenic patients. http://www.clinicaltrials.gov 2005. 3033769
91. Pagsberg A, Jagersma E, Baare W, Mackeprang T, Glenthoej by. Change in caudate nucleus volume after three-month treatment in drug- naive first-episode schizophrenia patients. Schizophrenia Research 2004;67(1):99. 3033771
92. Ropert R, Hoepfner Petersen HE, Benyay J. Where zuclopenthixol acetate stands amid the 'modified release' neuroleptics [Place de l'acetate de zuclopenthixol au sein des neuroleptiques a liberation modifiee]. Congres de Psychiatrie et de Neurologie de Langue Francaise, LXXXVIth Session; 1988 Jun 13-17; Chambery, France. 1988:350-62. [MEDLINE: 87290070; PMID 3615572]3033773
93. Rubio G, Martínez-Gras I, Ponce G, López-Muñoz F, Alamo C, Jimenez-Arriero MA, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term controlled study. European Neuropsychopharmacology 2005;15(Suppl 3):S476. 3033775
94. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]. Canada, 2006; Vol. 51, issue 8:531-9. [MEDLINE: 16933590]3033777
95. Rubio G, Martinez-Gras I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006. 3033778
96. Rubio G, Rodriguez-Jimenez R, Martinez-Gras I, Jimenez-Arriero MA, Palomo T. Prepulse inhibition of the startle response in amisulpride-treated patients: comparison with typical antipsychotics. Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28-Jul 2 ;Paris, France. 2009:394. 3033780
97. Rubioz G, Martine I, Recio A, Ponce G, Lopez-Munoz F, Alamo C, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study. European Journal of Psychiatry 2006;20(3):133-46. 3033782
98. Saxena B, MacCrimmon D, Busse E, Turner P, Cooper L, Kenny J, et al. I.M clopixol v/s modecate in chronic schizophrenia - a double-blind study. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990:247. 3033784
99. Saxena B. The value of depot neuroleptic injections in the treatment of chronic schizophrenia. Schizophrenia 1996 - Breaking down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver, Canada. 1996. [MEDLINE: 73210072; PsycINFO 1973-29665-001; PMID 4715636]3033786
100. Schooler NR, Keith SJ, Severe JB, Matthews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. International Congress on Schizophrenia Research 1993;9:260. 3033788
101. Shelton WH, Bishop MP, Gallant DM. The Achilles reflex and antipsychotic drugs. Current Therapeutic Research Clinical and Experimental 1969;11(1):22-6. [MEDLINE: 69084988; PMID 4973850]3033790
102. Singh I, Owino WJE. A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders. Journal of Intellectual Disability Research 1992;36:541-9. 3033792
103. Sofronov A, Spikina A, Savelyev A. The role of modern antipsychotics in correction of neurocognitive deficit in schizophrenia patients. European Psychiatry 2013; Vol. 28:1247. 3033794
104. Svestka J, Nahunek K, Ceskova E. Controlled cross-over comparison of oxyprothepine and clopenthixol decanoate in the prophylaxis of schizophrenic psychoses. Activitas Nervosa Superior 1986;28(1):35-6. [PsycINFO 75-08452]3033796
105. Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, ET AL. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32. [MEDLINE: 97179384; PMID 9027670]3033798
106. Taymeeyapradit U, Kuasirikul S. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. Journal of the Medical Association of Thailand 2002;85(12):1301-8. [MEDLINE: 2003183416]3033800
107. Tegeler J. A comparative trial of Cis(Z)-clopenthixol-decanoate and fluphenazine-decanoate. Pharmacopsychiatry 1985;18(1):78-9. [MEDLINE: 97179384; PMID 9027670]3033802
108. Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared to clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. Unpublished Report 1996. [MEDLINE: 74083340]3033804
109. Uys H, Berk M. A controlled double blind study of zuclopenthixol acetate compared with clothiapine in acute psychosis including mania and exacerbation of chronic psychosis. 20th Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1996 Jun 23-27; Melbourne, Australia. 1996. [MEDLINE: 74083340; PsycINFO 52-05954; PMID 4589640]3033805
110. Venkateswarlu T, Staley CJ, Neal CD. Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients:a dose-ranging study. International Journal of Geriatric Psychiatry 1990;5(4):265-70. 3033807
111. Viala A, Ba B, Durand A, Gouezo F, Hou N, Jorgensen A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 1988;94(3):293-7. [MEDLINE: 88190287; PMID 2895936]3033809
112. Walker CA. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out- patients. Pharmatherapeutica 1983;3(5):289-93. [MEDLINE: 83195220; PMID 6133287]3033811
113. Weiser G, Tahedl A, Reisecker F, Meyer H. Advantages of the initial therapy of acute schizophrenia with large doses of droperidol/A comparative study (author's transl) [Vorteile der Initialbehandlung akuter Schizophrenien mit hochdosiertem Droperidol. Eine Vergleichsstudie]. Arzneimittel Forschung 1975;25(11):1845-8. [MEDLINE: 76088237; PMID 1243093]3033813
114. Wistedt B, Koskinen T, Thelander S, Pedersen V, Molberg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia - a double-blind, multicenter study. Psychopharmacology 1990; Vol. 100, issue 4:23. 3033815
115. Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Molbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatrica Scandinavica 1991;84(1):14-21. [MEDLINE: 92025271; PMID 1681680]3033817
116. Xiaanoao G, Jiaju X, Mingshen W. Efficacy of clopenthixol in treating delusions and halucinations in schizophrenia. Journal of Clinical Psychology 1999;9(4):202-3. 3033819
117. Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clinical Neuropharmacology 1991;14(suppl.2):S16-S23. 3033821
118. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
119. Awad GA, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11(1):32-47.
120. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
121. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
122. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Science 1980;7:233.
123. da Silva Freire Coutinho E, Fenton M, Quraishi SN. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001164]
124. Dally P. Chemotherapy of Psychiatric Disorders. London: Logos Press Limited, 1967.
125. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
126. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
127. Dollery. Drug discovery and development in the molecular era. British Journal of Clinical Pharmacology January 1999;47(1):5-6.
128. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
129. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
130. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
131. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
132. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
133. Guy U. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
134. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
135. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
136. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
137. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine 1992;20(Monograph Supplement):1-97.
138. Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD000525.pub3]
139. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
140. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
141. Kozyrev VN, Smulevich AB, Drobizhev MIu, Kraeva GK, Kubrakov MA. Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects). Zhurnal Nevrologii Psikhiatrii Im S S Korsakova 2003;103(11):25-32.
142. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
143. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
144. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
145. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 1987;76(334):100.
146. Mace S, Taylor D. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. International Journal of Psychiatry in Clinical Practice 2005;9(2):124-9.
147. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
148. Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191-4.
149. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
150. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
151. Percudani M. Barbui C. Fortino I. Petrovich L. Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry 2005;38(3):128-31.
152. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
153. Taylor D, Kerwin R. Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol. Psychiatric Bulletin 2000;24:106-8.
154. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
155. Multiple. Pocket Guide to the ICD-10 Classification of Mental and Behavioural Disorders. 16. Elsevier, 2010.
156. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
157. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005474]